Relapsed Or Refractory Mantle Cell Lymphoma Therapeutics
1. Brukinsa patent expiration
Treatment: Treatment of adult patients with relapsed or refractory follicular lymphoma (fl), in combination with obinutuzumab, after two or more lines of systemic therapy; Treatment of adult patients with relaps...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9447106 | BEONE MEDICINES USA | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US11851437 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US10927117 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11701357 | BEONE MEDICINES USA | Treatment of B cell cancers using a combination comprising Btk inhibitors |
Jun, 2039
(13 years from now) | |
| US11884674 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US11911386 | BEONE MEDICINES USA | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11591340 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US10570139 | BEONE MEDICINES USA | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US11896596 | BEONE MEDICINES USA | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11786531 | BEONE MEDICINES USA | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11970500 | BEONE MEDICINES USA | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US11142528 | BEONE MEDICINES USA | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US12233069 | BEONE MEDICINES USA | Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor |
Jun, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-871) | Aug 31, 2024 |
| New Indication(I-874) | Sep 14, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| New Indication(I-817) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
| New Indication(I-936) | Mar 07, 2027 |
| Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
| Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
| Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
| ODE*(ODE*) | Mar 07, 2031 |
| Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Dosage: CAPSULE; TABLET
More Information on Dosage
BRUKINSA family patents
2. Jaypirca patent expiration
Treatment: Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (cll/sll) who have received at least two prior lines of therapy, including a btk inhibitor and a bcl-2 inhibitor; Treatme...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12220401 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(10 years from now) | |
| US10695323 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(10 years from now) | |
| US10342780 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10464905 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(10 years from now) | |
| US10918622 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(10 years from now) | |
| US12109193 | LOXO ONCOL | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide |
Sep, 2041
(15 years from now) | |
| US12268666 | LOXO ONCOL | Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2028 |
| Orphan Drug Exclusivity(ODE-424) | Jan 27, 2030 |
| Orphan Drug Exclusivity(ODE-451) | Dec 01, 2030 |
Drugs and Companies using PIRTOBRUTINIB ingredient
NCE-1 date: 27 January, 2027
Market Authorisation Date: 27 January, 2023
Dosage: TABLET
More Information on Dosage
JAYPIRCA family patents
3. Revlimid patent
expiration
Treatment: Use of revlimid (lenalidomide) while preventing the exposure of a fetus or other contraindicated individual to revlimid (lenalidomide); Use of revlimid (lenalidomide) for the treatment of mantle cell ...
REVLIMID's oppositions filed in EPO
REVLIMID IPR and PTAB Proceedings
Can you believe REVLIMID received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8288415 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione |
Jul, 2016
(9 years ago) | |
| US5635517 | BRISTOL MYERS SQUIBB | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Oct, 2019
(6 years ago) | |
| US7855217 | BRISTOL MYERS SQUIBB | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Nov, 2024
(1 year, 1 month ago) | |
| US7465800 | BRISTOL MYERS SQUIBB | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Apr, 2027
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6561976 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US7468363 | BRISTOL MYERS SQUIBB | Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(2 years ago) | |
| US9155730 | BRISTOL MYERS SQUIBB | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(2 years ago) | |
| US8589188 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US7119106 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline |
Jul, 2016
(9 years ago) | |
| US8626531 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US6755784 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US6555554 | BRISTOL MYERS SQUIBB | Isoindolines, method of use, and pharmaceutical compositions |
Jul, 2016
(9 years ago) | |
| US6908432 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US8648095 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor |
May, 2023
(2 years ago) | |
| US6281230 | BRISTOL MYERS SQUIBB | Isoindolines, method of use, and pharmaceutical compositions |
Jul, 2016
(9 years ago) | |
| US8315886 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US8204763 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US6045501 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(7 years ago) | |
| US6561977 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(5 years ago) | |
| US6315720 | BRISTOL MYERS SQUIBB | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct, 2020
(5 years ago) | |
| US8288415 | BRISTOL MYERS SQUIBB | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione |
Jul, 2016
(9 years ago) | |
| US9393238 | BRISTOL MYERS SQUIBB | Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent |
May, 2023
(2 years ago) | |
| US7189740 | BRISTOL MYERS SQUIBB | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
Apr, 2023
(2 years ago) | |
| US7968569 | BRISTOL MYERS SQUIBB | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(2 years ago) | |
| US8530498 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione |
May, 2023
(2 years ago) | |
| US8492406 | BRISTOL MYERS SQUIBB | Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(2 years ago) | |
| US9056120 | BRISTOL MYERS SQUIBB | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
Apr, 2023
(2 years ago) | |
| US9101621 | BRISTOL MYERS SQUIBB | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
May, 2023
(2 years ago) | |
| US5635517 | BRISTOL MYERS SQUIBB | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Oct, 2019
(6 years ago) | |
| US8404717 | BRISTOL MYERS SQUIBB | Methods of treating myelodysplastic syndromes using lenalidomide |
Apr, 2023
(2 years ago) | |
| US9101622 | BRISTOL MYERS SQUIBB | Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone |
May, 2023
(2 years ago) | |
| US8741929 | BRISTOL MYERS SQUIBB | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas |
Mar, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jun 05, 2020 |
| New Indication(I-672) | Jun 05, 2016 |
| New Strength(NS) | Jun 05, 2016 |
| New Indication(I-706) | Feb 17, 2018 |
| Orphan Drug Exclusivity(ODE-49) | Jun 05, 2020 |
| Orphan Drug Exclusivity(ODE-88) | Feb 17, 2022 |
| New Indication(I-796) | May 28, 2022 |
| New Indication(I-797) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-131) | Feb 22, 2024 |
| Orphan Drug Exclusivity(ODE-241) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-245) | May 28, 2026 |
Drugs and Companies using LENALIDOMIDE ingredient
Market Authorisation Date: 21 December, 2011
Dosage: CAPSULE
How can I launch a generic of REVLIMID before it's drug patent expiration?
More Information on Dosage
REVLIMID family patents